Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
Genocea is a biopharmaceutical company developing personalized cancer immunotherap...
Genocea is a biopharmaceutical company developi...
Caladrius is a clinical-stage biopharmaceutical company committed to the developme...
Caladrius is a clinical-stage biopharmaceutical...
The discovery of immunosuppressive (anti-rejection) drugs has made possible life-s...
The discovery of immunosuppressive (anti-reject...
SINTX Technologies is an OEM ceramics company that develops and commercializes sil...
SINTX Technologies is an OEM ceramics company t...
Personalis, Inc. is a growing cancer genomics company transforming the development...
Personalis, Inc. is a growing cancer genomics c...
We are an established, commercial-stage diagnostics company committed to reducing ...
We are an established, commercial-stage diagnos...
Fortress Biotech ("Fortress" or "the Company") is an innovative biopharmaceutical ...
Fortress Biotech ("Fortress" or "the Company") ...
Join the National Investor Network and get the latest information with your interests in mind.